ArticleCancer medicine2026
Mass Spectrometry-Driven Proteomic Biomarkers for Serum-Based Detection of Pancreatic Ductal Adenocarcinoma and Intraductal Papillary Mucinous Neoplasm-Associated Invasive Carcinoma.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPancreatic cancer remains a highly lethal malignancy due to late diagnosis and the lack of effective non-invasive biomarkers for detection, further complicated by biological heterogeneity, including intraductal papillary mucinous neoplasm (IPMN) and IPMN-associated invasive carcinoma (IPMC).
methodsSerum samples from a discovery cohort (n = 60), including patients with IPMN, IPMC, and pancreatic ductal adenocarcinoma (PDAC), were analyzed using LC-MS/MS-based serum proteomic profiling to identify candidate biomarkers. Feature selection was performed using ANOVA, receiver operating characteristic analysis, and permutation feature importance. The selected markers were further evaluated in an independent validation cohort (n = 40).
resultsIn the discovery cohort, the model demonstrated robust performance, with leave-one-out cross-validation AUROC values ranging from 0.814 to 1.000 across classifications of healthy controls and disease groups (IPMN, IPMC, and PDAC). In the independent validation cohort, the six-marker panel (CALR, FCN1, MBL2, SPP1, TAGLN2, and VWF) achieved an AUROC of 0.962 with a specificity of 95.0% for distinguishing healthy controls from IPMC, and an AUROC of 0.856 with a specificity of 90.0% for healthy controls vs. PDAC.
conclusionsThese findings demonstrate the robustness and clinical potential of the six-protein panel as a non-invasive diagnostic tool for pancreatic cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.